title: mTOR inhibition and its effect on cancer in transplantation.
abstract: A considerable amount of data indicates that transplanted patients are at increased risk for de novo and recurrent cancer. Treatment of this population is difficult. It remains unclear if the immunosuppressive therapy should be continued, tapered or even stopped or if immunosuppressive drugs with antiproliferative properties have beneficial effects in this situation. In various models, mTOR-inhibitors were shown to have immunosuppressive and anti-tumor effects. Here, we have reviewed the current literature trying to clarify if mTOR-inhibition brings advantages for the transplanted patients suffering from tumors.
authors.affiliation: Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
authors.forename: Joachim
authors.initials: J
authors.lastname: Andrassy
authors.forename: Christian
authors.initials: C
authors.lastname: Graeb
authors.forename: Markus
authors.initials: M
authors.lastname: Rentsch
authors.forename: Karl-Waller
authors.initials: KW
authors.lastname: Jauch
authors.forename: Markus
authors.initials: M
authors.lastname: Guba
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009369:Neoplasms / Q000503:physiopathology* / Q000601:surgery / Q000628:therapy; D016377:Organ Transplantation / Q000502:physiology*; D011494:Protein Kinases / Q000378:metabolism*; D020123:Sirolimus / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D014181:Transplantation Immunology
chemical_list: D007166:Immunosuppressive Agents; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus